Chemical Structure : RLY01
货号: PC-24244Not For Human Use, Lab Use Only.
RLY01 is a potent small-molecule REGγ-20S proteasome inhibitor, has affinity (KD) of 11.6 uM for 20S proteasome, blocks its degradation function, ultimately leading to cancer cell death.
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
RLY01 is a potent small-molecule REGγ-20S proteasome inhibitor, has affinity (KD) of 11.6 uM for 20S proteasome, blocks its degradation function, ultimately leading to cancer cell death.
RLY01 binds to and occupies the REGγ-bound pocket, suppressing REGγ-dependent 20S proteasome activity.
RLY01 blocks the degradation function of the REGγ-20S proteasome in a REGγ-dependent manner.
RLY01 blocks the growth of pan-KRAS–mutant tumors in vitro.
RLY01 increases the levels of the apoptosis-related proteins cleaved PARP (Cl-PARP) and cleaved caspase-3 (Cl-caspase-3) in KRAS-mutant cells in a concentration-dependent and REGγ-dependent manner, with no substantial effect on apoptosis in HCT116-REGγ-KO cells.
RLY01 treatment (25-50 mg/kg) effectively suppressed tumor growth in KRAS-mutant cancer models and lung cancer organoids.
The combination of RLY01 and the KRASG12C inhibitor AMG510 exhibited enhanced antitumor efficacy in KRASG12C cancer cells.
分子量 | 408.84 | |
分子式 | C21H17ClN4O3 | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
10 mM in DMSO |
1. Shen S, et al. J Clin Invest. 2025 Mar 17;135(6):e185278.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright